You asked "eventually". Of course it's possible in time.
But right now, No. Co.'s with $45M and zero debt don't go BK.
Forget the pre-clinical pipeline. It's all about the market for -130 diagnostic and the deal they make for -108. The diagnostic market would need to surprise to bring in significant revenues. Partnering -108 allows them to stay viable and pursue SOMETHING in pre-clinical. Hell they need to partner -108 just to get the share price up so they can do future ATM's. Unless they intend to sell 10's of millions of shares under $1.